What is morroniside and where does it come from?

Morroniside is a secoiridoid glycoside—a type of plant-derived bioactive compound—isolated primarily from the dried ripe fruit of Cornus officinalis (Asian dogwood or Asiatic cornelian cherry), where it occurs at concentrations of approximately 16.02 mg/g of plant material. The plant has been used in Traditional Chinese, Korean, and Japanese medicine for over 2,000 years, and morroniside is recognized as its principal pharmacologically active iridoid glycoside responsible for many of its documented biological effects.

What are the main health benefits of morroniside?

Preclinical research identifies several potential benefits: renoprotection in diabetic models through NF-κB inhibition and reduction of advanced glycation end products, neuroprotection at 10–100 μmol/L by reducing calcium overload and promoting neuronal survival, anti-platelet aggregation via cyclooxygenase and thromboxane B2 suppression, and pro-osteogenic effects in osteoblast cell lines. It is critical to note that all of these benefits are established only in cell culture and animal studies; no human clinical trials have confirmed these effects in people.

What is the bioavailability of morroniside and does it absorb well?

Morroniside has poor oral bioavailability, measured at only 3.6–7.0% in rat pharmacokinetic studies, meaning the vast majority of an oral dose does not reach systemic circulation intact. Intestinal absorption is pH-dependent and partially limited by efflux transporters including multidrug resistance proteins and breast cancer resistance protein (BCRP), with apparent permeability coefficients of 1.59–2.66 × 10⁻⁶ cm/s in Caco-2 cell models; no human pharmacokinetic data are currently available.

What is the recommended dosage of morroniside for humans?

No standardized human dosage has been established for isolated morroniside, as clinical trials in humans have not yet been conducted. Animal studies have used doses of 90–270 mg/kg body weight, which cannot be directly extrapolated to human supplementation without allometric scaling, safety studies, and clinical validation; morroniside is most commonly consumed as part of traditional Cornus officinalis preparations such as Liuwei Dihuang pills, where dosage is determined by traditional formulation guidelines under practitioner supervision.

Does morroniside help protect kidney health in people with diabetes?

Research in diabetic mouse models shows that morroniside reduces kidney damage by suppressing oxidative stress and preventing the buildup of harmful proteins called advanced glycation end products (AGEs). It works by modulating proteins that regulate fat metabolism in kidney cells and blocking inflammatory pathways. While these findings are promising, human clinical trials are still needed to confirm whether morroniside offers similar renoprotective benefits in diabetic patients.

What does the current scientific evidence say about morroniside's effectiveness?

Most evidence for morroniside comes from laboratory and animal studies, particularly research on diabetic kidney protection and neuroprotection mechanisms. Studies demonstrate it can reduce oxidative stress, inflammation, and metabolic dysfunction in cellular and animal models of disease. However, large-scale human clinical trials remain limited, so claims about effectiveness in people should be considered preliminary pending further research.

Who would benefit most from taking morroniside supplements?

Individuals with type 2 diabetes or metabolic disorders may be candidates for morroniside, given evidence of kidney protection in diabetic models. Those concerned with neurological health could also benefit, based on emerging research into its neuroprotective properties. However, anyone considering supplementation should consult a healthcare provider, particularly if they have existing kidney disease, diabetes, or are taking medications that affect kidney function.

Morroniside

Morroniside is a secoiridoid glycoside that exerts antioxidant, anti-inflammatory, and cytoprotective effects by modulating nuclear factor-kappa B signaling, inhibiting intracellular calcium overload, and suppressing advanced glycation end product formation. In diabetic animal models (db/db mice), morroniside at doses of 90–270 mg/kg demonstrated statistically significant reductions in oxidative stress markers and hypoglycemic effects (P < 0.01), while in vitro studies confirm neuroprotective activity at 10–100 μmol/L; however, no large-scale human clinical trials have yet validated these findings.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Morroniside is a secoiridoid glycoside isolated primarily from the fruit of Cornus officinalis (Asian dogwood, also called Asiatic cornelian cherry), a deciduous shrub native to China, Korea, and Japan. The plant thrives in temperate mountain regions at elevations between 400 and 1800 meters, particularly in the Zhejiang, Henan, and Shaanxi provinces of China. It has been cultivated for over 2,000 years in East Asia, both as an ornamental and medicinal plant, with the dried ripe fruit (known as Shanzhuyu in Traditional Chinese Medicine) serving as the primary source of morroniside at concentrations of approximately 16.02 mg/g of crude plant material.

Historical & Cultural Context

Cornus officinalis, the botanical source of morroniside, has been documented in Chinese medicine for over 2,000 years, appearing in classical texts including the Shennong Bencao Jing (Divine Farmer's Materia Medica), where the dried fruit (Shanzhuyu) was classified as a superior-grade tonic herb for the liver and kidney meridians. In Traditional Chinese Medicine, Shanzhuyu was prescribed to tonify the liver and kidneys, arrest sweating, stabilize essence, and treat conditions such as dizziness, tinnitus, soreness of the lumbar region, impotence, and excessive uterine bleeding—indications that align broadly with the compound's modern renoprotective and neuroprotective pharmacology. The fruit holds comparable significance in Korean traditional medicine (as Sansuyu) and Japanese Kampo medicine, where it is incorporated into classical formulas like Hachimi-jio-gan (equivalent to Liuwei Dihuang wan plus additional herbs). Modern phytochemical investigation beginning in the mid-20th century isolated morroniside as the primary iridoid glycoside responsible for many of the fruit's bioactivities, providing a molecular basis for its millennia-long medicinal reputation.

Health Benefits

- **Renoprotection in Diabetic Models**: Morroniside modulates renal sterol regulatory element binding proteins and suppresses NF-κB-driven oxidative stress, reducing triglyceride accumulation and advanced glycation end product (AGE) formation in the kidneys of diabetic db/db mice, suggesting a protective role against diabetic nephropathy.
- **Neuroprotection and Neurogenesis**: At concentrations of 10–100 μmol/L, morroniside promotes neuronal cell survival, increases axonal length, and enhances MTT metabolic rates in neuronal models, while also reducing lactate dehydrogenase release and inhibiting calcium-mediated excitotoxicity.
- **Antioxidant Activity**: Morroniside protects HEK293 and microglial cells against hydrogen peroxide-induced oxidative damage by scavenging reactive oxygen species and upregulating endogenous antioxidant defense pathways, demonstrating non-toxic activity across concentrations of 0.1–200 μM in vitro.
- **Hypoglycemic and Metabolic Regulation**: In diabetic animal models, morroniside reduces blood glucose levels and improves lipid profiles through suppression of NF-κB expression and reduction of AGE formation, indicating potential utility in metabolic syndrome management.
- **Anti-Platelet Aggregation**: Morroniside inhibits platelet aggregation by decreasing intracellular Ca²⁺ concentration, suppressing cyclooxygenase activity, and reducing thromboxane B2 synthesis, pathways relevant to cardiovascular risk reduction.
- **Bone Health Support**: In MC3T3-E1 osteoblast cell lines, morroniside promotes differentiation by increasing alkaline phosphatase activity, elevating collagen type I and osteocalcin content, and modulating caspase-mediated apoptosis, pointing to potential utility in osteoporosis models.
- **Pro-Angiogenic Effects**: At moderate to high doses (90–270 mg/kg in animal studies), morroniside promotes angiogenesis by upregulating endothelial-specific Tie-2 tyrosine kinase receptor expression, which may support tissue repair and wound healing processes.

How It Works

Morroniside exerts its primary cytoprotective effects through inhibition of the nuclear factor-kappa B (NF-κB) inflammatory signaling cascade, reducing downstream pro-inflammatory cytokine production and oxidative stress enzyme activation in renal and neural tissues. At the cellular level, it suppresses intracellular free calcium ion overload—a key mediator of neuronal excitotoxicity—while simultaneously reducing lactate dehydrogenase release as a marker of membrane integrity preservation. In metabolic contexts, morroniside modulates renal sterol regulatory element binding proteins (SREBPs) to limit lipid accumulation and inhibits the formation of advanced glycation end products, mechanisms that collectively attenuate diabetic organ damage. Its anti-platelet activity is mediated through concurrent suppression of cyclooxygenase enzymatic activity and thromboxane B2 biosynthesis alongside intracellular Ca²⁺ reduction, while its pro-osteogenic effects involve upregulation of alkaline phosphatase and osteocalcin expression with concomitant downregulation of apoptotic caspase pathways in osteoblasts.

Scientific Research

The evidence base for morroniside consists almost exclusively of in vitro cell culture studies and rodent animal models, with no published large-scale randomized controlled trials in humans identified as of the current literature review. Animal studies in db/db diabetic mice demonstrated statistically significant hypoglycemic and renoprotective effects at doses of 90–270 mg/kg (P < 0.01 and P < 0.05), and neuroprotection studies in rodent models showed consistent dose-dependent responses in the same dose range. Intestinal absorption has been characterized in Caco-2 cell monolayer models at concentrations of 5, 25, and 100 μM, establishing apparent permeability coefficients of 1.59–2.66 × 10⁻⁶ cm/s (apical-to-basolateral), with absolute oral bioavailability in rats measured at only 3.6–7.0%, raising significant questions about translational relevance to human supplementation. The overall evidence quality is preliminary; rigorous human pharmacokinetic studies, dose-finding trials, and placebo-controlled efficacy trials are needed before clinical recommendations can be made.

Clinical Summary

No human clinical trials with defined sample sizes, standardized dosing protocols, or reported effect sizes for morroniside as an isolated compound have been identified in the current literature. The compound's clinical investigation has been conducted entirely in preclinical settings: diabetic rodent models for metabolic and renal endpoints, isolated neuronal and osteoblast cell lines for mechanistic studies, and Caco-2 monolayers for absorption characterization. Traditional formulations containing Cornus officinalis—such as Liuwei Dihuang pills—have a longer history of human use and some clinical investigation, but these represent complex multi-herb preparations from which morroniside-specific effects cannot be isolated. Confidence in morroniside as a standalone therapeutic agent remains low pending human pharmacokinetic and efficacy data.

Nutritional Profile

Morroniside itself is a pure isolated iridoid glycoside compound (molecular formula C₁₇H₂₆O₁₁, molecular weight 434.37 g/mol) and does not constitute a macronutrient or micronutrient source in the conventional nutritional sense. In whole Cornus officinalis fruit, morroniside is present at approximately 16.02 mg/g dry weight alongside co-occurring iridoid glycosides including loganin and sweroside, which may compete for intestinal absorption transporters including multidrug resistance proteins and breast cancer resistance protein (BCRP). The fruit matrix also contains polysaccharides, ursolic acid, oleanolic acid, tannins, and anthocyanins, which may modulate both the absorption and bioactivity of morroniside in whole-food or crude extract contexts. Bioavailability of isolated morroniside is limited to 3.6–7.0% by the oral route in rats, with transport characterized as pH-dependent and partially mediated by efflux transporters, suggesting that food matrix components and pH-modifying co-administration could meaningfully alter absorption.

Preparation & Dosage

- **Traditional Aqueous Extract (Shanzhuyu)**: Dried Cornus officinalis fruit decocted in water, yielding approximately 16.02 mg/mL morroniside; used in TCM formulations such as Liuwei Dihuang pills at traditional doses determined by practitioner guidance.
- **Standardized Plant Extract Capsules/Tablets**: Available as Cornus officinalis extracts standardized for morroniside content; no universally accepted standardization percentage has been established in regulatory frameworks.
- **Isolated Morroniside (Research Grade)**: Used in preclinical studies at 90–270 mg/kg in rodents; no equivalent human dose has been validated or recommended.
- **Oral Bioavailability Note**: Absolute oral bioavailability is only 3.6–7.0% in rats, meaning effective tissue concentrations require substantially higher oral doses relative to intravenous equivalents; human bioavailability data are absent.
- **pH Consideration**: Aqueous preparations have an optimal pH of approximately 5.5; absorption is pH-dependent and may be reduced in alkaline gastrointestinal environments.
- **No Established Human Dose**: No regulatory agency or clinical guideline has established a standardized human supplemental dose for isolated morroniside; any use should be under qualified healthcare supervision.

Synergy & Pairings

Morroniside is traditionally administered as part of the Liuwei Dihuang pill formula alongside Rehmannia glutinosa, Dioscorea opposita, Alisma orientale, Poria cocos, and Paeonia suffruticosa, with the multi-herb combination hypothesized to enhance overall tonic and renoprotective effects through complementary and additive mechanisms not achievable by morroniside alone. Co-occurrence with other Cornus officinalis iridoids such as loganin may produce additive neuroprotective effects, though competitive transporter interactions at intestinal level could limit combined bioavailability. From a pharmacological synergy standpoint, morroniside's NF-κB inhibition and antioxidant activity may theoretically complement compounds with independent anti-glycation mechanisms—such as benfotiamine or carnosine—in diabetic nephropathy models, though no direct combination studies have been published.

Safety & Interactions

In vitro cytotoxicity assays demonstrate that morroniside is non-toxic to cell lines across concentrations of 0.1–200 μM, providing a preliminary safety signal at the cellular level, but comprehensive human safety data including adverse event profiles, tolerability across populations, and maximum tolerated doses have not been established in clinical studies. Potential pharmacokinetic drug interactions exist with substrates of multidrug resistance-associated proteins (MRPs, inhibited by MK571 and indomethacin) and breast cancer resistance protein (BCRP, inhibited by apigenin), meaning morroniside may alter the transport and plasma concentrations of co-administered drugs utilizing these efflux pathways. Competitive absorption interactions with co-occurring iridoid glycosides (loganin, sweroside) present in Cornus officinalis preparations may reduce morroniside bioavailability when taken as a whole-plant extract. No human data are available regarding safety in pregnancy, lactation, pediatric populations, or individuals with hepatic or renal impairment, and use in these populations cannot be recommended without further clinical investigation.